105 citations
,
October 2018 in “Nature” A small group of slow-growing cells causes basal cell carcinoma to return after treatment.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
2 citations
,
August 2002 in “British Journal of Ophthalmology” Tangent screens help detect visual field defects from vigabatrin.
Vinblastine and its metabolites may cause nausea and hair loss by binding to specific receptors and could lead to better chemotherapy drugs with fewer side effects.
November 2020 in “Journal of The American Academy of Dermatology” Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
6 citations
,
April 2013 in “Current Dermatology Reports” Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.
3 citations
,
April 2020 in “PubMed” Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.
3 citations
,
January 2025 in “SAGE Open Medical Case Reports” Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.
9 citations
,
October 2015 in “Cutaneous and ocular toxicology” Vemurafenib can cause scalp issues but can be managed without changing the dose.
7 citations
,
March 2023 in “Lasers in Surgery and Medicine” Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.
1 citations
,
May 2021 in “Scientific Reports” Certain cancer drugs are strongly linked to nerve damage, requiring close monitoring and early treatment.
2 citations
,
November 2025 in “Pharmacology Research & Perspectives” Avacopan may cause unexpected side effects, so early monitoring is important.
Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
12 citations
,
September 2020 in “Nanomaterials” The new drug delivery system improves vitiligo treatment by enhancing melanocyte activity and viability.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
January 2012 in “Journal of Clinical Medicine in Practice” The treatment is safe and effective for elderly patients with advanced non-small-cell lung cancer.
1 citations
,
October 2014 in “Annals of oncology” Paclitaxel and nab-paclitaxel can be safe and effective for advanced gastric cancer patients on hemodialysis.
25 citations
,
January 2021 in “Journal of drugs in dermatology” Sonidegib and vismodegib are similarly effective for advanced basal cell carcinoma, but sonidegib might have a slightly better safety profile.
February 2020 in “Central Plains Medical Journal” Thalidomide with CHOP is more effective for peripheral T-cell lymphoma than CHOP alone.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
January 1989 in “Side effects of drugs annual” Some cancer and immune system drugs can cause serious side effects, including heart, lung, nerve, and organ damage, which need careful monitoring and management.
93 citations
,
May 2010 in “European Journal of Cancer” BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
1 citations
,
March 2023 in “Medicine” The combination therapy is effective and well-tolerated for treating esophageal cancer.
9 citations
,
April 2010 in “Lung cancer” Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
32 citations
,
May 2023 in “Frontiers in Immunology” Understanding cellular interactions in VCA may lead to better treatments and reduce rejection.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.